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Interleukin-8 (IL-8) promotes cancer cell growth, survival, angiogenesis and metastasis 
in several tumors. Here, we investigated the sources of IL-8 production in multiple 
myeloma (MM) and its potential roles in MM pathogenesis. We found that bone marrow 
(BM) cells from patients with MM secreted higher amounts of IL-8 than healthy donors. 
IL-8 production was detected in cultures of CD138+ plasma cells and CD138- cells 
isolated from BMs of MM patients, and in three out of seven human myeloma cell lines 
(HMCLs) analyzed. Interactions between MM and stromal cells increased IL-8 
secretion by stromal cells through cell-cell adhesion and soluble factors. Interestingly, 
IL-8 expression also increased in HMCLs, stromal cells and osteoclasts after treatment 
with the anti-myeloma drugs melphalan and bortezomib. In fact, the effect of 
bortezomib on IL-8 production was higher than that exerted by stromal-MM cell 
interactions. Addition of exogenous IL-8 did not affect growth of HMCLs, although it 
protected cells from death induced by serum starvation through a caspase-independent 
mechanism. Furthermore, IL-8 induced by stromal-MM cell interactions strongly 
contributed to osteoclast formation in vitro, since osteoclastogenesis was markedly 
reduced by IL-8-specific neutralizing antibodies. In conclusion, our results implicate IL-
8 in myeloma bone disease and point to the potential utility of an anti-IL-8 therapy to 
prevent undesired effects of IL-8 upregulation on survival, angiogenesis and osteolysis 
in MM. 
 




Multiple myeloma (MM) is the second most common hematological malignancy with an 
annual incidence of 4 new cases per 100,000 people. MM is characterized by the 
accumulation of immunoglobulin-secreting clonal malignant plasma cells within the 
bone marrow (BM) and the evidence of end-organ damage, including osteolytic bone 
lesions, hypercalcemia, renal disease and anemia. 1-3 
Interactions between MM cells and BM cells have been widely reported to increase 
tumor growth, survival, migration, and drug resistance of myeloma cells. 1, 4, 5 These 
effects are mostly mediated by several cytokines, many of them induced by the 
interaction of myeloma cells with BM stromal cells (BMSCs). The network of cytokines 
includes several interleukins (IL-1β, IL-2, IL-3, IL-4, IL-6, IL-10, IL-11, IL-15 and IL-21), 
and other growth factors such as insulin-like growth factor (IGF-1), tumor necrosis 
factor α (TNF-α), transforming growth factor (TGF)-β, vascular endothelial growth 
factor (VEGF) and macrophage inflammatory protein (MIP)-1 α. Some of these soluble 
factors, such as TGF- β, IL-15 and IL-21, are produced and secreted by myeloma cells 
themselves. Others, like IGF-1, MIP-1 α, and IL-6 are mainly produced by the cells of 
the microenvironment. 1, 6 Finally, some cytokines like VEFG or TNF-α are produced by 
both types of cells. 
IL-6 is considered a major growth and survival factor for myeloma cells 1, 6. It is 
upregulated in BMSCs cells by either adhesion of MM cells or by soluble factors 7-9. 
The function of IL-6 as a survival factor has been demonstrated by its ability to inhibit 
spontaneous apoptosis and that induced by different conditions, like serum deprivation, 
treatment with dexamethasone or Fas cell-death receptor. 10-13 
IL-8, a member of the CXC chemokine family, was originally described as a neutrophil 
chemoattractant. 14 This cytokine is normally produced by a wide range of cells 
including lymphocytes, monocytes, endothelial cells, fibroblasts, hepatocytes and 
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keratinocytes. The overexpression of IL-8 in many tumors and cancer cell lines has led 
to investigate its role in tumor progression. 15-17 IL-8 has been shown to promote tumor 
growth, angiogenesis and metastasis in a variety of human cancers. 16, 18-21 Moreover, 
production of IL-8 by breast cancer cells has been found to increase osteoclast (OC) 
formation probably contributing to bone metastasis. 22, 23 In MM, BMSCs and 
endothelial cells from patients have been shown to secrete higher amounts of IL-8 than 
their healthy counterparts. 24, 25 However, the contribution of myeloma cells and their 
interaction with the microenvironment to IL-8 production has not been deeply analyzed. 
Regarding the role of IL-8 in MM cell proliferation, two reports have been published 
with contradictory results. In one study increased MM cell proliferation mediated by the 
presence of the chemokine was reported 25, whereas no differences in proliferation 
rates were observed in the other. 26 
Here, we investigated the sources of IL-8 production in MM and the potential role of 
this chemokine in MM pathogenesis. Our results showed that IL-8 was majorly induced 
on stromal cells after the interaction with MM cells, and was also upregulated in both 
myeloma and stromal cells by treatment with anti-myeloma drugs. The presence of 
recombinant IL-8 (rIL-8) neither affected growth of human myeloma cell lines (HMCLs) 
nor drug resistance. However, rIL-8 protected MM cells from cell death induced by 
serum starvation. Importantly, we also showed that IL-8 produced by the interaction 





Materials and methods 
 
Cells and culture conditions 
BM aspirates from healthy donors or patients with MM were obtained after written 
informed consent of participants. Aspirates were subjected to lysis to remove red blood 
cells, and resuspended in RPMI 1640-L-Glutamine medium supplemented with 10% 
fetal bovine serum (FBS) and antibiotics at an initial concentration of 7.5 X 105 cells/ml. 
Cells were grown at 37oC in a humidified atmosphere with 5% CO2. Supernatants were 
collected after 48 h of culture and stored at -20oC until use. When necessary, CD138+ 
plasma cells were isolated (purity >95%) from the bone marrow samples using the 
AutoMACS automated separation system (Miltenyi-Biotec). 
The HMCLs NCI-H929 and MM.1S were adquired from ATCC (American Type Culture 
Collection), and the rest of the HMCLs from DMSZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen). HMCLs were cultured in RPMI medium as 
described above. The human BM mesenchymal stromal cell line-TERT (hMSC-TERT) 
was a generous gift from Dr Campana (Department of Oncology and Pathology, St 
Jude Children's Research Hospital, Memphis, TN, USA)27. It was cultured in DMEM 
low-glucose supplemented with antibiotics and 10% FBS. The MM.1S-luc cell line was 
kindly provided by Dr Mitsiades (Dana-Farber Cancer Institute, Boston, MA, USA), 
whereas RPMI-8226-luc was lentivirally transduced to express firefly luciferase 28. 
 
Measurement of IL-8 in culture medium 
MM.1S, H929, JJN3, OPM2, U266, RPMI-8226 and IM9 (2 X 105 cells/ml) were 
cultured for three days. The supernatants were collected and analyzed for IL-8 
expression using a commercially available ELISA kit (R&D Systems, Minneapolis, MN, 
USA), according to manufacturer’s instructions. IL-8 concentrations below 2 pg/ml were 




Co-cultures of HMCLs with hMSC-TERT cells 
hMSC-TERT cells (1 X 105 cells) and HMCLs (2 X 105 cells) were co-cultured or 
cultured independently in 800 µl of RPMI medium for 24 h. In the experiments designed 
to identify which cell type was producing IL-8 in the co-culture system, either the h-
MSC-TERT cells or the HMCLs were mildly fixed by incubation with 1% 
paraformaldehyde for 10 min, extensively washed with PBS and co-cultured as 
described above. When physical contact in the co-culture wanted to be avoided, 100 µl 
of medium containing 5 X 104 MM cells was added to the upper chamber of a 24-
transwell plate (0.4 µm pore size; Costar) that contained in the lower chamber 600 µl of 
medium with adhered hMSC-TERT cells (1.2 X 105 cells). The system physically 
separated HMCLs from hMSC-TERT cells but allowed interaction between them by 
soluble factors. The supernatants were collected after 48 h of culture and measured for 
IL-8 secretion by ELISA. Cells were recovered and used for RNA extraction.  
 
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis 
To analyze IL-8 expression, total RNA was reverse transcribed to cDNA using a cDNA 
Reverse Transcription Kit from Applied Byosystems (Foster City, CA, USA). qRT-PCR 
was performed using iQ™ SYBR® Green Supermix kit (Bio-Rad, Hercules, CA, USA), 
the iQ5 PCR detection system, and the following gene-specific primers: IL-8, forward 5' 
GTGCAGTTTTGCCAAGGAGT-3´ and reverse 5'- CTCTGCACCCAGTTTTCCTT-3´ 
GAPDH, forward 5'- GGGTGGAATCATATTGGAACATGTA-3' and reverse 5'-. 
CAGGGCTGCTTTTAACTCTGGTAA-3'. Relative expression of IL-8 was normalized to 
GAPDH using the 2-∆Ct method, where ∆Ct= Ct IL-8-Ct GAPDH).  
Reagents  
rIL-8, anti-IL-8 and anti-IL-6 antibodies were purchased from R&D Systems. rIL-6 was 
obtained from PeproTech (London, UK). Melphalan and dexamethasone were obtained 
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from Sigma-Aldrich (St. Louis, MO, USA) and bortezomib (Velcade) was obtained from 
the Pharmacy of the University Hospital of Salamanca. Anti-Fas was obtained from 
Upstate-Millipore (Billerica, MA, USA). Macrophage colony-stimulating factor (M-CSF) 
and receptor activator of NF-kB ligand (RANKL) were supplied by PeproTech. BAY 11-
7082 and PS-1145 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). 
 
Cell proliferation and cell viability assays 
Cell proliferation in the presence of rIL-8 or IL-8 blocking antibodies, was determined 
by cell counting after 48 or 72 h of culture. Alternatively, cell growth was monitored by 
BrdU incorporation, quantitation of ATP (CellTiter-Glo, Promega, madison, WI, USA) or 
by measurement luminescence of RPMI-8226-luc and MM.1S-luc HMCLs. Cell viability 
in the presence of drugs was assessed by the MTT assay. Cell survival in the absence 
of serum and in the presence of rIL-8, rIL-6 or the corresponding blocking antibodies 
was determined by trypan blue exclusion and apoptosis by annexin V-
isothiocyanate/propidium iodide (PI) double staining, according to manufacturer´s 
procedure (Immunostep, Salamanca, Spain).  Caspase-3 activity was determined using 
a colorimetric assay kit provided by Promega. 
 
In vitro osteoclast formation assay  
Peripheral blood mononuclear cells (PBMCs) were isolated from blood of healthy 
donors after centrifugation with Ficoll-Paque™ (GE Healthcare, Uppsala, Sweden). 
Cells were resuspended at 1.5 X 106 cells/ml in alpha-minimum essential (α-MEM) 
medium containing 10% FBS, and cultured overnight in 96-well plates (100 µl of cell 
suspension per well). Adherent cells were then cultured in the same medium in the 
presence of M-CSF (25 ng/ml) as a negative osteoclastogenic control; addition of 
recombinant RANKL (rRANKL) (50 ng/ml) was assayed as a positive control for 
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osteoclasts formation. Conditioned medium (CM) from IM9-hMSC-TERT direct co-
cultures was assayed at 1:4 dilution and rIL-8 or IL-8-blocking antibodies were assayed 
at 50 ng/ml and 25 µg/ml, respectively. CM contained 10 ± 0.3 ng/ml of IL-8, as 
measured by ELISA. Anti-IL-8 was added to some of the CM-containing wells. The 
concentration used, 25 µg/ml, completely blocked the IL-8 found in CM, as determined 
by ELISA. Medium was replaced twice a week and cultures were terminated on day 21. 
Plates were stained for tartrate resistance acid phosphatase (TRAP) (Sigma) and 
multinucleated TRAP+ cells (≥ 3 nuclei) were counted as osteoclast.   
Statistical analysis 
Differences between the data were assessed for statistical significance using the 
Student's unpaired two tailed t-test with the Simfit statistical software version 7.0.5 






Expression of IL-8 in MM and normal plasma cells (NPCs)  
Using microarrays expression data from our previous studies 
(http://www.ncbi.nlm.nih.gov/geo; GEO accession number: GSE47552), IL-8 mRNA 
was found to be upregulated in CD138+ PCs isolated from patients with MM compared 
to NPCs (Figure 1A). 29 In contrast, the expression of IL-6 mRNA was similar in NPCs 
and multiple myeloma plasma cells (MMPCs). Overexpression of IL-8 in CD138+ PCs 
from several MM patients was verified by qRT-PCR (Figure 1B). Then, secretion of IL-8 
was measured by ELISA in culture supernatants from BM cells obtained from 15 MM 
patients and 10 healthy donors. We found that BM cells from MM patients secreted 
statistically significant higher amounts of IL-8 than those from healthy donors, whose 
IL-8 levels were non-detectable in most of the cases (Figure 1C, D). However, no 
correlation was found between levels of IL-8 and the percentage of PCs present in the 
BM of each patient. In fact, BMs with the highest proportion of PCs (more than 80%) 
secreted less amounts of IL-8 than others with lower PC infiltration. This result 
suggested that although high levels of IL-8 were associated with the presence of 
MMPCs, these cells might not be the main producers in the BM.   
 
Direct cell contact between MMPCs and the remaining BM cells increased IL-8 
secretion  
Interactions between MM cells and BM cells have been shown to enhance the 
production of IL-6 10 and other angiogenic factors, such as VEGF or hepatocyte growth 
factor (HGF). 8, 30, 31 To determine whether IL-8 was also induced as a consequence of 
the interaction between myeloma cells and the remaining BM cell populations, IL-8 
levels were quantified by ELISA in the 24 h culture supernatant collected from the 
same number of CD138+ MMPCs and CD138- cell fraction cultured separately or 
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together (direct co-culture) (Figure 2). The assays carried out in three different patients 
showed that CD138- cells secreted higher amounts of IL-8 than CD138+ cells, 
suggesting that BM cell populations other than myeloma cells were the major IL-8 
producers. In addition, IL-8 levels were further increased after co-culture of both types 
of cells, indicating that CD138- cells, CD138+ cells or both favored the production of IL-
8 when cultured together.  
 
Adhesion of MM cell lines to mesenchymal stromal cells triggered IL-8 secretion 
ELISA quantification of IL-8 in the conditioned medium (CM) from different HMCLs 
showed that IL-8 production was low in IM9, JJN3 and RPMI-8226, and undetectable in 
the CM from all other HMCLs (Figure 3A).  
To analyze whether adherence of HMCLs to stromal cells induced IL-8 secretion, four 
MM cell lines (IM9, RPMI-8226, JJN3 and U266) were cultured alone or together with 
the stromal hMSC-TERT cell line. IL-8 secretion increased approximately 3-4-fold when 
RPMI-8226, JJN3 or U266 were in contact with the stromal cell line, and nearly 30-fold 
when the IM9 cell line was co-cultured with hMSC-TERT cells compared to hMSC-
TERT cells alone (Figure 3B). To determine the identity of the cells that increased IL-8 
production, HMCLs or hMSC-TERT cells were fixed with paraformaldehyde before the 
co-cultures, according to a protocol previously described for other cytokines or growth 
factors 8, 32. Fixation of hMSC-TERT cells before co-culture with RPMI-8226, JJN3 or 
IM9 abolished IL-8 production (Figure 3C). In contrast, fixation of RPMI-8226 or JJN3 
did not significantly inhibit IL-8 overproduction induced by the co-culture. These results 
indicated that stromal cells were the major source of IL-8, and that IL-8 secretion, when 
stromal cells were co-cultured with RPMI-8226 or JJN3, was mainly induced by cell-cell 
adhesion. However, fixation of IM9 cells markedly reduced IL-8 production induced by 
the co-culture with hMSC-TERT cells, which suggested that soluble factors might also 




Soluble factors contributed to IL-8 overproduction in co-cultures of IM9 with 
hMSC-TERT cells  
To further investigate the IL-8 secretion induced by the interaction of IM9 with hMSC-
TERT cells, co-cultures were established using transwell inserts, which prevent contact 
of both types of cells but allow the diffusion of soluble factors. Secretion of IL-8 was 
found highly increased when cells were co-cultured in the absence of physical contact 
(Figure 3D, MSC+IM9 TW), although to a lesser extent than that observed by direct 
cell-cell contact (Figure 3D, MSC+IM9). These results confirmed that induction of IL-8 
in co-cultures of IM9 with hMSC-TERT cells was dependent on both cell-cell adhesion 
and soluble factors. To identify the cells responsible for the increased IL-8 production in 
the absence of physical contact, IL-8 mRNA expression was quantified in IM9 and 
stromal cells separately recovered after the transwell co-culture (Figure 3E). IL-8 
mRNA levels were upregulated in both IM9 and hMSC-TERT cells as a result of the 
interaction between the two cell types in the absence of cell contact, although induction 
was much higher in hMSC-TERT cells.  
It has been previously shown that induction of IL-6 secretion from BMSCs triggered by 
MM cell adhesion is mediated through NF-κB. 33 Likewise, IL-8 production by stromal 
cells in the presence of BM culture supernatants from MM patients was dependent on 
NF-kB signaling 26. So we expected that this transcription factor would also be 
implicated in IL-8 overexpression observed in hMSC-TERT cells co-cultured with IM9. 
Thus, we found that the NF-κB inhibitor BAY 11-7082 partially blocked the IL-8 
upregulation observed in hMSC-TERT cells after the co-culture with IM9 cells, which 
confirmed that NF-κB was involved in the production of IL-8 in hMSC-TERT cells 
triggered by MM cell interactions (Figure 3F).  
IL-8 secretion was induced by treatment with anti-myeloma drugs 
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It has been described that expression of IL-8 is induced by treatment with paclitaxel in 
non-small cell lung cancer (NSCLC) 34 and ovarian carcinoma cells. 35 Likewise, 
increased expression of IL-8 mRNA has been recently reported after treatment of MM 
cells with lenalidomide 36. These observations prompted us to investigate the effect of 
other anti-myeloma drugs in IL-8 secretion. We found that treatment of RPMI-8226 and 
IM9 cells with bortezomib or melphalan increased IL-8 expression (Figure 4A). 
However, IL-8 upregulation was found to be NF-κB-independent since treatment of 
these HMCLs with the NF-κB inhibitor BAY 11-7082, at the inhibitory concentration of 5 
µM 37, 38, did not suppress either the bortezomib or the melphalan-induced IL-8 
expression (Figure 4B). Similar results were obtained with the specific IKKβ inhibitor 
PS-1145 (20 µM) 37(data not shown). We then explored whether stromal cells and 
osteoclasts, as components of the BM microenvironment, also increased IL-8 
expression after treatment with the anti-myeloma drugs. As shown in Figure 4B, the 
presence of these drugs clearly induced IL-8 expression in the two cell types, although 
IL-8 induction caused by melphalan required higher doses than those employed in MM 
cells. Next, we analyzed IL-8 secretion in MM cell lines and in the stromal cell line 
hMSC-TERT cultured alone or co-cultured in the absence or the presence of 
bortezomib and melphalan (Figure 4C). We observed that bortezomib increased IL-8 
secretion by MM cells and stromal cells when cultured alone, whereas melphalan at 30 
µM only induced IL-8 overexpression in MM cells, in accordance with the qRT-PCR 
data. Interestingly, we found that IL-8 secretion significantly augmented in bortezomib-
treated co-cultures compared to those left untreated, indicating that the effect of this 
drug was higher than the effect of the co-culture on IL-8 production. Therefore, 
bortezomib induced IL-8 overexpression in hMSC-TERT cells and MM cells cultured 
separately or co-cultured. In order to give support to this finding in an in vivo setting, we 
also analyzed the effect of bortezomib on IL-8 secretion of BM cells isolated from three 




rIL-8 protected MM cells from cell death induced by serum starvation through a 
caspase-independent mechanism 
IL-8 has previously been reported to function as an autocrine growth factor for different 
normal and tumor cells. 39-41 However, the role of IL-8 in MM cell proliferation is 
controversial. 25, 26 We found that neither rIL-8 addition nor anti-IL-8 neutralizing 
antibodies affected cell proliferation of HMCLs as measured by cell counting (Figure 
5A), BrdU incorporation, ATP quantification, or when the effect of rIL-8 or anti-IL-8 was 
assayed in RPMI-8226-luc and MM.1S-luc cells (data not shown). Similarly, addition of 
rIL-8 did not stimulate growth of myeloma cells even at low serum concentration (1%) 
(data not shown). 
Previous studies have demonstrated that IL-6 protects myeloma cells from cell death 
induced by treatment with anti-myeloma drugs, from spontaneous and Fas-mediated 
apoptosis, as well as from cell death induced by serum starvation 10-13. We first 
investigated the effects of IL-8 on MM cell sensitivity to melphalan in RPMI-8226 
(Figure 5B), MM.1S, JJN3 and IM9 cell lines (data not shown). Addition of rIL-8 did not 
affect cell death induced by melphalan (Figure 5B, left panel), even when the amounts 
of rIL-8 added exceeded those induced by the treatment (Figure 4A). On the other 
hand, treatment with anti-IL-8 neutralizing antibodies had no effect on cell death 
induced by the drug (Figure 5B, right panel). No protection against cell death was 
observed after treatment with different concentrations of bortezomib, dexamethasone, 
Fas ligand or when spontaneous cell death was analyzed (data not shown). However, 
we observed that rIL-8 clearly prevented cell death induced by serum starvation in a 
similar way to IL-6, which was used as a positive control (Figure 5C, left panel). As 
expected, cell death protection was abrogated by addition of anti-IL6 or anti-IL-8 
neutralizing antibodies (Figure 5C, right panel). When apoptosis was analyzed using 
Annexin V/PI staining, we found that addition of rIL-8 clearly protected MM cells from 
apoptotic cell death induced by serum starvation (Figure 5D). Interestingly, caspase 3 
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was activated after serum deprivation, even when rIL-8 was added to the media (Figure 
5E). These results indicated that IL-8 protected HMCLs from apoptosis induced by 
serum deprivation via a caspase-independent mechanism.                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
rIL-8 stimulated growth of osteoclasts precursors and IL-8 induced by the 
interaction of MM cells with stromal cells strongly contributed to osteoclasts 
formation in vitro 
To analyze the role of IL-8 in osteoclastogenesis we first investigated whether this 
chemokine influenced the growth of osteoclasts precursors using PBMCs cultured with 
M-CSF in the absence or in the presence of different concentrations of rIL-8. After 7 
days of culture, cell density was increased according to the concentrations of the 
chemokine (Figure 6A), which was corroborated measuring proliferation by the MTT 
assay (Figure 6B). 
In order to ascertain the relative contribution of IL-8 induced by the interaction of MM 
cells with stromal cells to osteoclasts differentiation, CM from IM9-hMSC-TERT co-
cultures, with and without IL-8 neutralizing antibody was added to human PBMCs 
cultured in the presence of M-CSF. We found that the CM from the co-culture induced 
osteoclasts formation (Figure 7A) as also did rIL-8 (Figure 7B), whereas anti-IL-8 
antibody significantly reduced the number of osteoclasts provoked by the CM (Figure 




In this study we showed that interactions between myeloma and stromal cells triggered 
IL-8 overexpression. This chemokine, induced in stromal cells by adhesion of MM cells 
and also by soluble factors, increased myeloma cell survival in serum-starvation 
conditions and highly contributed to osteoclast formation. Moreover, we found that 
treatment with anti-myeloma drugs also stimulated IL-8 overexpression.  
Production of IL-8 by cancer cells has been shown in melanoma, colon carcinoma, liver 
and pancreatic cell lines. 39, 42-44 In this study, we showed using qRT-PCR that MM cells 
isolated from several patients expressed higher levels of IL-8 than those isolated from 
healthy donors, confirming the overexpression of this chemokine in primary MM cells 
previously observed by expression microarrays. 29, 45 Secretion of IL-8 was detected in 
PCs isolated from patients with MM and in some HMCLs, and interactions between 
stromal and myeloma cells significantly increased the production of this chemokine. 
Stromal cells were the major source of IL-8, as also described for VEGF and HGF 30, 31, 
which highlights the importance of these cells in producing angiogenic factors. In 
IM9/hMSC-TERT co-cultures, IL-8 secretion was mainly increased in stromal cells by 
both cell adhesion and soluble factors, which is analogous to the secretion pattern 
described for IL-6. 8 Levels of IL-8 transcripts also increased in IM9 cells after co-
cultures established in the absence of physical contact. These findings are in 
agreement with the results described in NSCLC, in which tumor/stromal co-cultures 
induced IL-8 production, in pulmonary fibroblast and in certain NSCLC cell lines. 46 
According to previous published results for IL-6 and IL-8, we found that IL-8 
upregulation in stromal cells due to interaction with IM9 cells was partially mediated by 
the transcription factor NF-kB. 26, 33 
Interestingly, IL-8 expression was also induced by treatment of MM cells, stromal cells, 
and osteoclasts with bortezomib or melphalan. Bortezomib-induced IL-8 expression 
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was also observed in BM cells isolated from MM patients. Overexpression of IL-8 by 
MM cells after treatment with lenalidomine has previously been described 36, and 
expression of IL-8 has also been reported to be induced by treatment with paclitaxel in 
solid tumors. 34, 35 A recent study also found induction of IL-8 in ovarian cells by 
treatment with bortezomib although this effect was not observed in HMCLs 47, in 
disagreement with our results. We speculate that the discrepancy could be related to 
the high concentrations of bortezomib used by Singha et al, which would result in MM 
cell death before IL-8 induction. IL-8 upregulation by paclitaxel has been described to 
be mediated, at least in part, by the drug-mediated activation of NF-kB, a known 
inducer of IL-6 and IL-8 expression. 48, 49 NF-kB activation has also been reported when 
MM cells were treated with melphalan 50, and also when ovarian cancer cell lines and 
HMCLs were treated with bortezomib 47, 51, suggesting that IL-8 upregulation induced 
by treatment with these two drugs in MM could also respond to NF-kB activation. 
Surprisingly, we found that chemical inhibition of NF-kB did not suppress either 
bortezomib or melphalan-induced IL-8 overexpression. Our results indicate that other 
transcriptional or post-transcriptional mechanisms must be responsible for the 
chemokine upregulation in MM and highlight the fact that mechanisms governing IL-8 
expression may differ among different cell types. 47, 52 In this regard, a recent study has 
reported that bortezomib induced IL-8 expression in human monocytes and 
macrophages through a mechanism p38 MAPK-dependent and NF-kB-independent 53.  
We have shown that neither rIL-8 addition nor inhibition of this chemokine by 
neutralizing antibodies, affected the proliferation of HMCLs, contrary to the data 
reported for other tumor cell lines 39, 41-44 and also in MM. 25 However, our results are in 
agreement with a previous study showing no effect of IL-8 on MM cell proliferation 
despite the presence of IL-8 receptors on different HMCLs. 26 We observed that IL-8 
clearly enhanced survival of myeloma cells in the absence of serum, as also described 
for IL-6. 13 Neutralizing antibodies avoided the protective effect of IL-8 against cell 
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death induced by serum deprivation, indirectly supporting the presence of IL-8 
receptors (CXCR1/CXCR2) on HMCLs. It is possible that the signaling pathways that 
promote IL-8 mediated-cell growth may be non-functional in MM cells, whereas those 
that enhance survival in the absence of growth factors could be fully operative. The 
effect of IL-6 in survival and protection from drug-mediated apoptosis has been 
attributed to the activation of JAK-STAT and PI3K/Akt signaling cascades. 1However, 
its role in the protection of cell death induced by growth factor withdrawal has not been 
characterized. Here, we showed that protection of IL-8 against cell death induced by 
serum deprivation did not depend on inhibition of caspase activation, in agreement with 
some reports that showed the existence of caspase-independent cell death under 
serum free conditions. 54, 55 We found that IL-8 did not protect MM cells from apoptosis 
induced by chemotherapeutic agents. The fact that bortezomib and also melphalan 
induce caspase-dependent apoptosis in MM 56, 57 makes it tempting to speculate that 
IL-8 could only block myeloma apoptosis induced by caspase-independent 
mechanisms. 
It has previously been described that rIL-8 induces osteoclasts formation. 22, 23 In this 
study we observed, first, that rIL-8 acts as a growth factor for osteoclasts precursors, 
which could eventually differentiate to functional osteoclasts in bone-resorbing areas at 
sites of myeloma growth; and second, that the CM from myeloma-stromal co-cultures 
triggered osteoclast differentiation. Neutralization of IL-8 by the correspondent 
antibodies markedly reduced osteoclasts formation, which revealed that the 
osteoclastogenic activity of the CM was mainly induced by IL-8. We found that r-IL-8 
reproduced the effect of the CM, and directly stimulated osteoclastogenesis 
independent of RANKL, in agreement with previous reports. 22, 23   
In summary, we showed that interactions between myeloma and stromal cells, and 
treatment with anti-myeloma drugs triggered IL-8 overexpression. BM stromal cells 
were the major source of IL-8 in stromal-MM co-cultures.  However, we cannot exclude 
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the possibility that other cells in the BM microenvironment, in addition to stromal cells, 
might contribute to IL-8 production. This is in fact indirectly suggested by the high 
content of IL-8 in the CM of BM cultures from myeloma patients (Figure 1C), and also 
by the elevated serum levels of IL-8 found in MM patients 58, 59. In this study, we 
present evidence of osteoclastogenesis promotion by IL-8 from myeloma and stromal 
cultures and anti-apoptotic effects of IL-8 on serum-deprived myeloma cells. These 
findings, together with the angiogenic and MM cell chemotactic roles of IL-8 25, 26, 
suggest that anti-IL-8 therapy might be beneficial to prevent undesired effects of IL-8 
upregulation due to interactions of myeloma cells with the microenvironment or 
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Figure 1. Expression and secretion of IL-8 in MM. A: IL-8 and IL-6 gene expression by 
microarray analysis in PCs derived from healthy donors or MM patients (CD138+-
isolated cells). Gene expression was determined by microarray analysis. Data are the 
average ± SD of 5 NPCs and PCs from 74 MM samples. (*** p<0.001). B: Expression 
levels of IL-8 quantified by qRT-PCR. Expression of IL-8 was normalized to GAPDH 
and presented as 2-ΔCt. C: IL-8 levels, assessed by ELISA, in culture supernatants of 
BM cells obtained from healthy donors and patients with MM. Percentage of PC 
infiltration for each sample is indicated. D: Box plot representation of IL-8 levels 
showed in C. (*** p<0.001). 
Figure 2. Interactions between MM cells and stromal cells induce IL-8 overproduction. 
CD138+ PCs and CD138- cells were isolated from three patients with MM using 
inmunomagnetic beads. CD138+ cells (1 X 105) and CD138- cells (1 X 105) were 
cultured independently or together in 200 µl of culture medium. IL-8 was measured 
after 24 h of culture by ELISA. Data are shown as mean ± SD from duplicates. (** 
p<0.01, * p<0.05). 
Figure 3. Interactions between HMCLs and stromal cells increase IL-8 secretion. A: IL-
8 levels in culture supernatants of HMCLs measured by ELISA. B: Cells from the 
indicated HMCLs and hMSC-TERT cells (MSC) were cultured independently or 
together in 800 µl of culture medium. IL-8 levels were determined after 24 h of culture 
by ELISA. Data shown are mean ± SD from three independent experiments. (*** 
p<0.001; ** p<0.01 compared to MSC). C: Same as (B) but with hMSC-TERT cells or 
HMCLs mildly fixed with paraformaldehyde (indicated as F). Data are the mean of three 
independent experiments (*** p<0.001 compared to MSC). D: IL-8 levels in CM from 
hMSC-TERT cells, IM9 cells or direct or transwell (TW) co-cultures. E: IL-8 expression 
levels in hMSC-TERT or IM9 cells quantified by qRT-PCR in the specified conditions.  
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F: hMSC-TERT cells (4x105) per well were plated in 6-well dishes and allowed to form 
an adherent monolayer over 24 h. Then hMSC-TERT cells and IM9 cells (6 x 105) were 
pretreated 3 h with non-lethal concentrations of BAY 11-7082 (5 µM and 3 µM, 
respectively) and cultured independently or co-cultured with 3 µM BAY 11-7082 for an 
additional 24 h in RPMI medium. Finally, MM cells were mechanically detached from 
the hMSC-TERT, leaving the monolayer undisturbed and IL-8 expression was 
quantified in hMSC-TERT cells by qRT-PCR. Data in D, E and F are means ± SD from 
three independent experiments (*** p<0.001; ** p<0.01).  
Figure 4. Upregulation of IL-8 by treatment with bortezomib and melphalan. A: IL-8 
expression in RPMI-8226 and IM9 cells pretreated or not 12 h with BAY 11-7082 
before 24 h incubation with the indicated doses of bortezomib and melphalan. BAY 11-
7082 was used at 5 µM in RPMI-8226 cells and at 3 µM in IM9 cells B: IL-8 expression 
in hMSC-TERT cells (MSC) and osteoclasts after 24 h of culture in the absence (UT) or 
the presence of the indicated drugs. Osteoclasts were obtained from PBMCs after 21 
days of culture in osteogenic medium containing M-CSF (25 ng/ml) and RANKL (50 
ng/ml). C: HMCLs and hMSC-TERT cells (MSC) were cultured independently or co-
cultured in 800 µl of culture medium in the absence (UT) or the presence of the 
indicated drugs. IL-8 levels were determined after 24 h of culture by ELISA. Data are 
means ± SD from three independent experiments (*** p<0.001 compared to UT cells; ** 
p<0.01; * p<0.05). D: IL-8 secretion by BM cells isolated from three MM patients 
treated or not (UT) with bortezomib for 24 h.  
Figure 5. rIL-8 affects neither the growth rate of MM cells nor their resistance to anti-
myeloma drugs, but protects them from cell death induced by serum starvation.  A: Cell 
growth of IM9 and JJN3 cell lines. Cells were plated at 5 X 104 cells/ml in 24-well plates 
and cultured with medium alone or medium containing rIL-8 (100 ng/ml) or anti-IL-8 (5 
µg/ml). Cell number was determined after 48 and 72 h of culture. Values correspond to 
mean cell number ± SD of triplicates. B: Survival of RPMI-8226 cells to melphalan after 
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72 h of culture in the presence of IL-8 (panel 1) or anti-IL-8 neutralizing antibodies 
(panel 2) assessed by MTT. C: Cells were plated at 1 X 105 cells/ml in serum-free 
medium and survival was determined at indicated times by trypan blue exclusion. 
Recombinant IL-6, rIL-8 or the corresponding neutralizing antibodies were used when 
indicated at 100 ng/ml (IL-6 and IL-8) or 5 µg/ml (IL-6 or IL-8 neutralizing antibodies). 
D: Cell death in JJN3 and H929 cells determined by Annexin/PI double staining after 
72 h of culture in serum-free medium and in the same medium supplemented with rIL-8 
(100 ng/ml). Percentages of annexin-/PI- (live cells) correspond to the mean ± SD of 
three independent experiments (** p< 0.01 compared to untreated cells). 
Representative experiments are shown. E: Caspase 3 activation in JJN3 and H929 at 
the indicated times of culture in serum-free medium in the absence or in the presence 
of rIL-8 (100 ng/ml).  
Figure 6. rIL-8 stimulates the growth of osteoclasts precursors. A: Representative 
micrographs of osteoclasts precursors stained with hematoxylin/eosin (HE). PBMCs 
were cultured in osteogenic medium containing M-CSF (25 ng/ml) and the indicated 
concentrations of rIL-8 for 7 days. B: Cell viability was evaluated at the indicated 
conditions by the MTT assay (* p< 0.05 compared to M-CSF-treated cells). 
Figure 7. IL-8 induced by interactions between HMCLs and hMSC-TERT cells strongly 
contributes to osteoclasts formation. A: PBMCs were cultured in osteoclastogenic 
medium with M-CSF (25 ng/ml), or in the same medium containing either RANKL (50 
ng/ml) or CM from IM9-hMSC-TERT cultures at 1:4 dilution. Anti-IL-8 was added to 
some of the CM-containing wells. Percentage of TRAP+ multinucleated cells (≥ 3 
nuclei) is indicated. A total of 400 cells were counted per treatment group. The 
experiment was performed in triplicate. (* p<0.05, compared to wells containing only M-
CSF). B: Osteoclasts formation induced by rIL-8 or RANKL. The experiment was 
performed as described in A, but with rIL-8 (50 ng/ml). C: Representative micrographs 
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